key: cord-0751203-h0n99phq
authors: Lin, Weiyin; Xie, Zhiwei; Li, Yueping; Li, Liya; Wen, Chunyan; Cao, Yi; Chen, Xiaoting; Ou, Xu; Hu, Fengyu; Li, Feng; Tang, Xiaoping; Cai, Weiping; Li, Linghua
title: Association between detectable SARS‐COV‐2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019
date: 2020-07-27
journal: J Med Virol
DOI: 10.1002/jmv.26307
sha: 054164f4efa5fdde3ea357d068ca623f85429546
doc_id: 751203
cord_uid: h0n99phq

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA was found in the intestines and feces, but its clinical significance is not completely clear. We aim to characterize the longitudinal test results of SARS‐CoV‐2 RNA in anal swabs and to explore the association with disease severity. METHODS: We included laboratory‐confirmed coronavirus disease 2019 (COVID‐19) patients, who were hospitalized in Guangzhou Eighth People's Hospital and excluded those who had not received anal swabs for SARS‐COV‐2 RNA testing. Epidemiological, clinical, and laboratory data were obtained. Throat swabs and anal swabs were collected periodically for SARS‐COV‐2 RNA detection. RESULTS: Two hundred and seventeen eligible patients (median aged 50 years, 50.2% were females) were analyzed. 21.2% (46/217) of the patients were detected with SARS‐CoV‐2 RNA in anal swabs. The duration of viral RNA was longer, but the viral load was lower in anal swabs than throat swabs in the early stage of the disease. During a median follow‐up of 20 days, 30 (13.8%) patients were admitted to the intensive care unit (ICU) for high‐flow nasal cannula or higher‐level oxygen support measures to correct hypoxemia. Detectable viral RNA in anal swabs (adjusted hazard ratio [aHR], 2.50; 95% confidence interval [CI], 1.20‐5.24), increased C‐reactive protein (aHR, 3.14; 95% CI, 1.35‐7.32) and lymphocytopenia (aHR, 3.12; 95% CI, 1.46‐6.67) were independently associated with ICU admission. The cumulative incidence of ICU admission was higher among patients with detectable viral RNA in anal swabs (26.3% vs 10.7%, P = .006). CONCLUSION: Detectable SARS‐CoV‐2 RNA in the digestive tract was a potential warning indicator of severe disease.

Conclusion: Detectable SARS-CoV-2 RNA in the digestive tract was a potential warning indicator of severe disease.

anal swab, COVID-19, disease severity, SARS-CoV-2 RNA 1 | BACKGROUND During the last few months, coronavirus disease 2019 (COVID-19) has become a global public health threat and caused millions of infections and deaths. 1 Research has revealed that the pathogen is a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), belonging to the same family of viruses responsible for the SARS and the Middle East respiratory syndrome (MERS). [2] [3] [4] Although most cases are mild with a good prognosis, the mortality rate of severe patients is considerable. 5 At present, no vaccines or specific antiviral drugs are available for prevention or treatment of COVID-19.

Early differentiation of severe cases from mild cases is very helpful to reduce the mortality rate. However, effective early warning indicators of severe disease are still lacking so far.

SARS-CoV-2 RNA can be detected not only in the respiratory tract, but also in the blood, digestive tract, and feces. [6] [7] [8] Several studies have found that the positive rate of SARS-CoV-2 RNA in anal swabs (AS) is higher than that in nasopharyngeal swabs and sputum samples during convalescence, [9] [10] [11] suggesting that SARS-CoV-2 might actively infect and replicate in the gastrointestinal (GI) tract. 12 Wong et al 13 found patients with more severe disease tended to have a higher detection rate of fecal SARS-CoV-2 RNA. Our previous study suggests that detectable SARS-CoV-2 RNA in blood is an indicator of further clinical severity. 14 So, the relationship of viral load between the respiratory tract and digestive tract, and its association with the severity of the disease is still unclear.

In this study, we aimed to characterize the longitudinal test results for SARS-CoV-2 RNA in the digestive tract and to explore the association between detectable viral RNA and disease severity in patients with COVID-19.

Guangzhou Eighth People's Hospital is one of the designated hospitals for patients with COVID-19 and hospitalized around 85% of the confirmed cases in Guangzhou. All patients were diagnosed with COVID-19 by means of reverse-transcriptase polymerase chain reaction (RT-PCR) assayed in throat swabs (TSs) before hospitalization, according to World Health Organization interim guidance and the new coronavirus pneumonia prevention and control program (in Chinese). 15, 16 We retrospectively included laboratory-confirmed cases with COVID-19 from 20 January to 20 February 2020, and excluded patients who did not have AS tests during hospitalization. Patients were followed up until 1 June 2020, or the day when patients recovered and discharged from hospital, or were transferred to the designated hospital for critically ill patients, or died. This study was approved by the Ethics Committee of Guangzhou Eighth People's Hospital. Written informed consent was obtained from all screened patients.

TSs and ASs were collected periodically for SARS-COV-2 RNA detection.

Virological detection was carried out on the platform of Da'an Gene Corporation, Sun Yat-sen University, Guangzhou, China. Viral RNA extraction and RT-PCR were performed following the standard protocol. 14,17 Viral RNA was extracted with a Nucleic Acid Isolation Kit on an automatic workstation Smart 32, both being provided by Da'an Gene Corporation, Sun Yat-sen University. A 200 μL sample was used for extraction following the standard protocol, and viral RNA was finally eluted with 60 μL elution buffer. RT-PCR reagent was used following the 5′-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3′) separately, were added into the same reaction. 18, 19 Positive and negative controls were included for each batch of detection. A cycle threshold value (C t value) of 40 or more for both genes was defined as negative, and a C t value of less than 40 for both genes was defined as positive. Samples with a single C t value less than 40 required confirmation by retesting.

The medical records, nursing records, and laboratory reports of patients were analyzed to obtain data of demographic status (eg, age and gender), underlying comorbidities (eg, diabetes, hypertension, and cardiovascular disease), epidemiological characteristics (eg, recent exposure history), clinical symptoms and signs (eg, fever, cough, and dyspnea), laboratory findings (eg, complete blood count, coagulation test, and blood chemistry), chest computed tomographic scans and treatment measures (eg, antiviral therapy, corticosteroid therapy, and respiratory support). Data were entered into a computerized database and reviewed by a trained team of physicians. 

Data were expressed as counts and percentages for categorical variables and as mean and standard deviation or median and interquartile range (IQR) for continuous variables. Qualitative and quantitative differences between subgroups were analyzed using the χ 2 test or Fisher's exact tests for categorical parameters and Student t test or Mann-Whitney test for continuous parameters, as appropriate. Cox regression models were performed to evaluate the association between baseline parameters and ICU admission. The logrank test was performed to examine differences in the risk of ICU admission. All statistical tests were two-sided. Statistical significance was taken as P < .05. All analyses were performed with SPSS software, version 26.0 (IBM, Armonk, NY). . The prevalence of GI symptoms that occurred during hospitalization was higher in patients with detectable than those with undetectable SARS-CoV-2 RNA in ASs (47.8% vs 25.7%, P = .004). The difference was mainly contributed by anorexia (26.1% vs 12.3%, P = .021) and diarrhea (21.7% vs 11.7%, P = .080). Patients with detectable SARS-CoV-2 RNA in ASs had higher levels of systolic and diastolic blood pressure and higher proportions of hypertension (34.8% vs 19.3%, P = .026) compared with those with undetectable tests. Other comorbidities like diabetes (6.5% vs 8.2%, P = .709), cardiovascular disease (6.5% vs 3.5%, P = .363), chronic liver disease (6.5% vs 7.0%, P = .906), chronic kidney disease (2.2% vs 2.3%, P = .947), and pulmonary tuberculosis (2.2% vs 1.2%, P = .512) were comparable between these two groups. Other characteristics between them are shown in Table 1 . In brief, the demographic status, epidemiological characteristics, clinical symptoms and signs, laboratory and imaging findings, and treatments were comparable between the two groups.

The longitudinal changes of SARS-CoV-2 RNA in ASs and TSs among the 46 patients who had detectable viral RNA in ASs are shown in 

Of the 217 hospitalized patients with COVID-19, 201 (92.6%) patients were diagnosed with mild/moderate status, and 16 (7.4%) A recent study has found that angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 attachment and entry. 3 Besides the lung, ACE2 is also present in the epithelia of the small were observed before the digestive tract. 24 Kipkorir et al summed up the recent evidence of prolonged SARS-CoV-2 detection in anal/rectal swabs and stool specimens in COVID-19 patients after negative conversion in nasopharyngeal RT-PCR test and found that the pooled prevalence estimate for prolonged rectal/anal/stool SARS-CoV-2 RNA was 32%, highlighting the potential of GI shedding of the virus even in asymptomatic patients. 25 Peng et al detected SARS-CoV-2 RNA in urine and blood specimens and anal and oropharyngeal swabs. Although they found symptoms related to infection of these systems may not be present, they still believed testing different specimen types may be useful for monitoring disease changes and progression, and for establishing a prognosis. 26 Our longitudinal study found a positive coloration between ASs and disease severity, further supporting their conclusion.

Consistent with previous reports, 9, 10, 27 we found the duration of viral was longer in ASs than in TSs, suggesting persistent fecal viral shedding and potential fecal-oral transmission.

The transmission ability of the virus is greatly correlated with the viral load. However, little is known about the viral load of SARS-CoV-2

in the digestive tract. In this study, we found the C t values were higher in ASs than those in TSs in the early stages of COVID-19. The high Ct values in ASs approximately indicated low levels of virus in these specimens. 11 In the middle and later stages of the disease, there was no significant difference in viral load between them, and both tended to be negative. It is suggested that during the recovery period of the disease, the virus in the respiratory tract and digestive tract are gradually eliminated. However, it is still uncertain when the patient will not be contagious. As we only detected the viral RNA but could not isolate the In summary, we found a longer duration of the virus but lower viral load in the digestive tract than in the respiratory tract, and 

Health Organization coronavirus disease 2019 (COVID-19) situation report-152

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Clinical characteristics of coronavirus disease 2019 in China

Detection and analysis of nucleic acid in various biological samples of COVID-19 patients

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Covid-19 and the digestive system

Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: a meta-analysis

Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity

clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. Accessed April 30, 2020. 16. National Health Commission. New coronavirus pneumonia prevention and control program

Product center of Da'an Gene Corporation, Sun Yat-sen University

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Diarrhea is associated with prolonged symptoms and viral carriage in corona virus disease 2019

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Multi-omics evaluation of gastrointestinal and other clinical characteristics of SARS-CoV-2 and COVID-19

First case of 2019 novel coronavirus in the United States

Detection of SARS-CoV-2 by RT-PCR in anal from patients who have recovered from coronavirus disease 2019

Prolonged SARS-Cov-2 RNA detection in anal/rectal swabs and stool specimens in COVID-19 patients after negative conversion in nasopharyngeal RT-PCR test

SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology

Persistence of viral RNA in stool samples from patients recovering from covid-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Predicting illness severity and shortterm outcomes of COVID-19: a retrospective cohort study in China

Viral and host factors related to the clinical outcome of COVID-19

Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin

Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease

The authors declare that there are no conflict of interests.

LL, WC, and WL conceived the study and designed the protocol. XT and YL gave instructions. ZX contributed to statistical analysis and interpretation of data. LL and WL drafted the manuscript. FL, FH, and LL were in charge of nuclear acid RT-PCR. YL and CW reviewed the data independently. YC, XC, and XO contributed to conducting the study and collecting data. All authors had full access to the final version of the manuscript and agreed to its submission.

http://orcid.org/0000-0003-3262-1760Zhiwei Xie http://orcid.org/0000-0001-7302-4132